Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc. develops and commercializes medical technologies for the surgical market, including soft tissue repair, wound irrigation and bone fusion products used in operating rooms and sterile environments. Company news commonly covers financial results and guidance, sales and distribution activity, contracts for BIASURGE Advanced Surgical Solution, clinical and economic evidence for CellerateRX Surgical Powder, and product portfolio initiatives such as OsStic.
Coverage also includes conference presentations and business realignment disclosures, including the treatment of Tissue Health Plus as discontinued operations in Sanara's financial statements.
Sanara MedTech (Nasdaq: SMTI) reported second quarter 2026 net revenue of $28.1 million, up 9% year-over-year, with gross profit of $26.2 million and a 93% gross margin. Operating income was $1.8 million, while net loss from continuing operations was $0.4 million, or $0.05 per diluted share.
For the first six months of 2026, net revenue rose 14% to $55.9 million, gross profit reached $52.0 million (93% margin) and operating income was $4.4 million. Adjusted EBITDA was $5.0 million for the quarter and $9.3 million year-to-date. Sanara ended June 30, 2026 with $15.4 million in cash and $46.5 million of long-term debt and has classified Tissue Health Plus operations as discontinued. Management also highlighted a signed agreement under which Sanara is expected to be acquired by MIMEDX, subject to customary closing conditions.
MIMEDX (Nasdaq: MDXG) reported second quarter 2026 net sales of $64 million, down 35% from $98.6 million a year earlier. Surgical product revenue grew 15% year over year, led by AMNIOFIX and AMNIOEFFECT, while Wound sales fell 61% due to Medicare reimbursement changes effective January 1.
Gross profit was $44.4 million with a 69% margin versus 81% a year ago. SG&A declined to $59.8 million, but higher bad debt expense contributed to a net loss of $14.8 million, compared with $9.6 million of net income in the prior-year quarter. Cash and cash equivalents were $135.8 million at June 30, 2026.
MIMEDX also agreed to acquire Sanara MedTech (Nasdaq: SMTI) for $35 per share in cash and stock, implying about $350 million enterprise value. Each Sanara share will receive $33.00 in cash plus 0.4735 MIMEDX shares, a 46% premium to Sanara’s 30-day VWAP. MIMEDX plans to fund the cash portion with cash on hand and a new $300 million term loan from Hayfin, and reaffirmed 2026 net sales guidance of $260–$290 million with full-year Adjusted EBITDA expected to approach breakeven.
MIMEDX (Nasdaq: MDXG) and Sanara MedTech (Nasdaq: SMTI) signed a definitive merger agreement under which MIMEDX will acquire all outstanding Sanara shares in a cash-and-stock deal valued at $35 per share, implying an enterprise value of about $350 million and a 46% premium to Sanara’s 30-day VWAP.
Sanara holders will receive $33.00 in cash plus 0.4735 MIMEDX shares per Sanara share. MIMEDX plans to fund the cash portion with cash on hand and a new $300 million term loan from Hayfin, replacing its existing credit facility. The companies expect the combination to nearly double MIMEDX’s surgical revenue, push 2027 combined revenue above $400 million with adjusted EBITDA margin over 20%, and generate over $20 million in run-rate cost synergies. The boards of both companies unanimously approved the deal, which is expected to close by year-end, subject to Sanara shareholder and regulatory approvals.
Sanara MedTech (Nasdaq: SMTI) reported first quarter 2026 net revenue of $27.8 million, up 19% year-over-year, with gross margin of 93% and operating income of $2.6 million.
Net income from continuing operations was $0.4 million ($0.04 per diluted share), and Adjusted EBITDA was $4.3 million. Soft tissue repair products drove 21% sales growth, while bone fusion products declined 2%. Cash was $13.6 million with $46.2 million long-term debt at March 31, 2026.
Sanara guided second quarter 2026 net revenue to $28.5–$29.5 million (10–14% growth) and reaffirmed full-year 2026 net revenue guidance of $116–$121 million (13–17% growth).
Sanara MedTech (Nasdaq: SMTI) will report first quarter 2026 financial results on May 12, 2026 before U.S. markets open and will host a conference call and webcast at 8:00 a.m. ET.
The call will cover the quarter ended March 31, 2026, include a Q&A, offer telephonic and online replays, and the webcast will be available via the company investor relations site.
Sanara MedTech (Nasdaq: SMTI) reported fourth-quarter and full-year 2025 results and reaffirmed 2026 guidance. Full-year net revenue rose 19% to $103.1M, Adjusted EBITDA was $17.0M, and the company reaffirmed 2026 revenue guidance of $116M–$121M (≈13%–17% growth).
Management highlighted commercial expansion, Vizient Innovative Technology contracting for BIASURGE, planned U.S. launch of OsStic in 1Q2027 pending FDA clearance, and increased R&D investment.
Sanara MedTech (Nasdaq: SMTI) announced publication of a peer-reviewed Journal of Medical Economics study (March 11, 2026) evaluating CellerateRX Surgical Powder for high-risk spine surgery wounds. The one-year economic model (2025 USD) found $3,852 cost savings, a 0.007 QALY gain, and a $4,542 net monetary benefit per patient; readmissions and revisions accounted for $2,238 and $835 of savings. Probabilistic analysis showed dominance in >99% of simulations.
Sanara MedTech (Nasdaq: SMTI) will report its fourth quarter and full year 2025 financial results on March 24, 2026 before U.S. markets open. The company will host a conference call and webcast on March 24, 2026 at 8:00 a.m. ET to discuss results for the quarter and year ended December 31, 2025 and answer questions.
Dial-in details, replay instructions, and a live webcast link are provided; an online replay will be available for approximately one year.
Sanara MedTech (Nasdaq: SMTI) will present at the TD Cowen 46th Annual Health Care Conference in Boston. Management is scheduled to deliver a presentation on Tuesday, March 3, 2026 at approximately 9:10 a.m. ET.
Presentation materials and a live audio webcast will be posted to the company’s Investor Relations website prior to the presentation, and an archived replay will be available after the conference.
Sanara MedTech (Nasdaq: SMTI) reported unaudited preliminary results for Q4 and full-year 2025 and issued full-year 2026 guidance. Q4 2025 revenue is expected to be $27.2M–$27.7M (up ~3%–5%; or +11%–13% ex-$1.8M BIASURGE 2024 sales). FY 2025 revenue is expected at $102.7M–$103.2M (≈19% growth; ≈21%–22% ex the $1.8M item). Cash was ≈$16.6M and long-term debt ≈$46.0M at 12/31/2025. Operational highlights include a Vizient Innovative Technology contract for BIASURGE and continued work with Biomimetic Innovations on OsStic, targeted for U.S. commercial introduction in Q1 2027 pending FDA clearance. 2026 revenue guidance is $116M–$121M (+13%–17% vs 2025 midpoint). The results remain unaudited and subject to final audit adjustments.